Targeted Complement Inhibition with Homodimeric Minimal Factor H During Porcine Normothermic Machine Perfusion Attenuates Renal Ischemia-Reperfusion Injury

Background: The alternative pathway (AP) of complement activation is a key driver in the pathogenesis of ischaemia-reperfusion injury (IRI). Factor H (FH) acts as the principal regulator of the AP. This study evaluates the efficacy of a novel homodimeric minimal FH (HDM-FH) construct (previously shown to control the AP in several mouse models) within a high-fidelity, ex-vivo human-relevant model of renal injury. Methods: In a randomised study, 5 mg of HDM-FH was administered during 6-hour autologous whole blood-based normothermic machine perfusion (NMP) of porcine kidney pairs recovered following circulatory death. Renal physiology, markers of complement activation (soluble (s)C5b-9, tissue Bb, and C1q deposits), immune cell infiltration (neutrophils, macrophages, and T-cells), glycocalyx shedding, and markers of cell death were assessed and compared against controls. Results: HDM-FH administration resulted in no adverse effects on renal physiology. Treatment significantly reduced complement activation, evidenced by decreased sC5b-9 in perfusate (p=.048) and urine (p=.031), as well as reduced tissue deposits of Bb (p=.009) and intriguingly, C1q (p=.005). This inhibition correlated with a significant reduction in immune cell infiltration, including neutrophils (p=.015), macrophages (p=.021), and T-cells (p=.04). Furthermore, downstream indicators of IRI were improved, with attenuated glycocalyx shedding (p=.028) and reduced cell death (p=.001) at the conclusion of NMP. Conclusions: These findings demonstrate that HDM-FH effectively controls complement activation during IRI in a human-relevant model. By blocking the immunopathological cascade, localized real-time complement inhibition provides significant downstream benefits in reducing immune infiltration and cellular injury. Therefore, HDM-FH holds therapeutic potential for mitigating complement-mediated injury following transplantation.

Authors

Publication Details

Journal
Newcastle University ePrints (Newcastle Univesity)
Published
2026-11-16
DOI
https://doi.org/10.25405/ncl.35023732
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeted Complement Inhibition with Homodimeric Minimal Factor H During Porcine Normothermic Machine Perfusion Attenuates Renal Ischemia-Reperfusion Injury

Harriet Denton, Kevin J. Marchbank, Rolando Berlinguer‐Palmini, Neil Sheerin et al.
1 links
Newcastle University ePrints (Newcastle Univesity)
Complement system in diseases
article

Targeted Complement Inhibition with Homodimeric Minimal Factor H During Porcine Normothermic Machine Perfusion Attenuates Renal Ischemia-Reperfusion Injury

Harriet Denton, Kevin J. Marchbank, Rolando Berlinguer‐Palmini, Neil Sheerin, Lucy Bates, Madison Cooper, Beth Gibson, Chloe Connelly, Tom-Erik Mollnes, Yi Yang, Min Wu, Emily Thompson, Kirstin Pettersen, Georgios Kourounis, Samuel Tingle, Balaji Mahendran, Colin Wilson
article en

Abstract

Background: The alternative pathway (AP) of complement activation is a key driver in the pathogenesis of ischaemia-reperfusion injury (IRI). Factor H (FH) acts as the principal regulator of the AP. This study evaluates the efficacy of a novel homodimeric minimal FH (HDM-FH) construct (previously shown to control the AP in several mouse models) within a high-fidelity, ex-vivo human-relevant model of renal injury. Methods: In a randomised study, 5 mg of HDM-FH was administered during 6-hour autologous whole blood-based normothermic machine perfusion (NMP) of porcine kidney pairs recovered following circulatory death. Renal physiology, markers of complement activation (soluble (s)C5b-9, tissue Bb, and C1q deposits), immune cell infiltration (neutrophils, macrophages, and T-cells), glycocalyx shedding, and markers of cell death were assessed and compared against controls. Results: HDM-FH administration resulted in no adverse effects on renal physiology. Treatment significantly reduced complement activation, evidenced by decreased sC5b-9 in perfusate (p=.048) and urine (p=.031), as well as reduced tissue deposits of Bb (p=.009) and intriguingly, C1q (p=.005). This inhibition correlated with a significant reduction in immune cell infiltration, including neutrophils (p=.015), macrophages (p=.021), and T-cells (p=.04). Furthermore, downstream indicators of IRI were improved, with attenuated glycocalyx shedding (p=.028) and reduced cell death (p=.001) at the conclusion of NMP. Conclusions: These findings demonstrate that HDM-FH effectively controls complement activation during IRI in a human-relevant model. By blocking the immunopathological cascade, localized real-time complement inhibition provides significant downstream benefits in reducing immune infiltration and cellular injury. Therefore, HDM-FH holds therapeutic potential for mitigating complement-mediated injury following transplantation.

Newcastle University ePrints (Newcastle Univesity)
Good health and well-being
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon